JP Morgan Trims Molecular Device Rating

Analyst David Molowa says the near-term outlook is hazy for the medical-instruments maker

JP Morgan cut Molecular Device (MDCC ) to long-term buy from buy.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.